325 related articles for article (PubMed ID: 18391747)
1. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
Motoi N; Szoke J; Riely GJ; Seshan VE; Kris MG; Rusch VW; Gerald WL; Travis WD
Am J Surg Pathol; 2008 Jun; 32(6):810-27. PubMed ID: 18391747
[TBL] [Abstract][Full Text] [Related]
2. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
3. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
5. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
6. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
7. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
Travis WD; Brambilla E; Noguchi M; Nicholson AG; Geisinger KR; Yatabe Y; Beer DG; Powell CA; Riely GJ; Van Schil PE; Garg K; Austin JH; Asamura H; Rusch VW; Hirsch FR; Scagliotti G; Mitsudomi T; Huber RM; Ishikawa Y; Jett J; Sanchez-Cespedes M; Sculier JP; Takahashi T; Tsuboi M; Vansteenkiste J; Wistuba I; Yang PC; Aberle D; Brambilla C; Flieder D; Franklin W; Gazdar A; Gould M; Hasleton P; Henderson D; Johnson B; Johnson D; Kerr K; Kuriyama K; Lee JS; Miller VA; Petersen I; Roggli V; Rosell R; Saijo N; Thunnissen E; Tsao M; Yankelewitz D
J Thorac Oncol; 2011 Feb; 6(2):244-85. PubMed ID: 21252716
[TBL] [Abstract][Full Text] [Related]
8. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
[TBL] [Abstract][Full Text] [Related]
9. The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma.
Clay TD; Do H; Sundararajan V; Moore MM; Conron M; Wright GM; McLachlan SA; Dobrovic A; Russell PA
J Thorac Oncol; 2014 May; 9(5):654-63. PubMed ID: 24722155
[TBL] [Abstract][Full Text] [Related]
10. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
11. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
[TBL] [Abstract][Full Text] [Related]
12. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Zakowski MF; Hussain S; Pao W; Ladanyi M; Ginsberg MS; Heelan R; Miller VA; Rusch VW; Kris MG
Arch Pathol Lab Med; 2009 Mar; 133(3):470-7. PubMed ID: 19260752
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
Chantranuwat C; Sriuranpong V; Huapai N; Chalermchai T; Leungtaweeboon K; Voravud N; Mutirangura A
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S322-9. PubMed ID: 16623049
[TBL] [Abstract][Full Text] [Related]
15. Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung.
Kobayashi N; Toyooka S; Ichimura K; Soh J; Yamamoto H; Matsuo K; Otani H; Jida M; Kubo T; Tsukuda K; Kiura K; Sano Y; Date H
J Thorac Oncol; 2008 Jul; 3(7):704-10. PubMed ID: 18594314
[TBL] [Abstract][Full Text] [Related]
16. Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases.
Nakamura H; Saji H; Shinmyo T; Tagaya R; Kurimoto N; Koizumi H; Takagi M
Clin Lung Cancer; 2015 May; 16(3):209-15. PubMed ID: 25467929
[TBL] [Abstract][Full Text] [Related]
17. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
De Oliveira Duarte Achcar R; Nikiforova MN; Yousem SA
Am J Clin Pathol; 2009 May; 131(5):694-700. PubMed ID: 19369630
[TBL] [Abstract][Full Text] [Related]
18. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
[TBL] [Abstract][Full Text] [Related]
19. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD
Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
